Devices

FDA Nixes Enforcement Action Against Whoop's Blood Pressure Feature

FDA has formally closed an enforcement action against Whoop Inc., reversing an earlier regulatory position that raised questions about whether the company's Blood Pressure Insights feature should be regulated as a medical device. In a recently issued closeout letter, FDA informed the wearable technology company that it had completed its evaluation of corrective actions taken in response to a previous warning letter and considers the matter resolved. The action effectively ends a closely watched dispute over the regulatory status of wellness-focused blood pressure estimation tools.

The agency had previously issued a Warning Letter arguing that Whoop's Blood Pressure Insights feature crossed the line from a general wellness product into a regulated medical device by providing users with information related to blood pressure. FDA expressed concerns that consumers could rely on the feature for medical decision-making despite the product lacking FDA clearance or approval.

The Warning Letter became a focal point in broader debates over how FDA should regulate emerging digital health technologies, particularly consumer wearables that generate health-related insights using algorithms and physiological data collected from sensors.

In the closeout letter, FDA indicated that the agency is satisfied with the company's corrective actions and does not intend to pursue further enforcement related to the matter. While a closeout letter does not constitute FDA clearance, approval, or endorsement of a product, it signals that the agency considers the issues identified in the Warning Letter to have been adequately addressed.

Specifically, FDA’s recent letter said: “Based on changes your firm has made to your ‘Blood Pressure Insights’ product (BPI) and its labeling in response to our Warning Letter dated July 14, 2025, and consistent with the Food and Drug Administration’s updated guidance document, General Wellness: Policy for Low Risk Devices, FDA does not intend to enforce the device statutory and regulatory requirements for your BPI product as modified.”

The decision could be viewed as a notable development for the digital health industry, which has sought greater regulatory clarity around wellness features that provide health metrics without explicitly diagnosing, treating, or preventing disease.

The case also comes as FDA has been reevaluating several digital health and software policies under new agency leadership. Industry observers have been watching closely for signs that the agency may adopt a more flexible approach toward consumer-facing health technologies, particularly those that provide informational insights rather than direct clinical measurements.

Whoop has positioned Blood Pressure Insights as a wellness-oriented feature designed to help users understand trends in their cardiovascular health rather than replace traditional blood pressure cuffs. The company has maintained that the feature is not intended to diagnose hypertension or serve as a substitute for medical care.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome